Samalizumab
Monoclonal antibody
AstraZenecaSamalizumab is one of 30 small molecule programs targeting Acute Myeloid Leukemia. It is currently in development.
1
Indications
3
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Neupogen
EEastern Cooperative Oncology Group
Phase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Tibsovo
SServier
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Dalalone
CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3
ALL-Trans Retinoic Acid (ATRA)
IncytePhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Recombinant FLT3 Ligand
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Samalizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Company